The Problem: Various retinal conditions, including retinal detachment, require a vitrectomy: surgical removal of the vitreous humor to access and repair the retina. The vitreous is then replaced with a substitute material to ensure the retina stays attached during recovery. Current clinical substitutes – gases and silicone oils – cause significant discomfort during patient recovery, including blurred vision, extensive head posturing, risk of glaucoma, and follow-up surgeries. As a result, patients are precluded from work, leisure activities, and air travel for several weeks or longer. There is a significant unmet need for a new biomimetic vitreous substitute to improve patient recovery following retinal surgery.

Our Solution: Synakis’ novel biomaterial SNK-125 is a promising alternative to the suboptimal materials currently used in the clinic. SNK-125 is injectable, transparent, biocompatible, biodegradable, non-swelling, and fully compatible with current vitreoretinal surgical procedures. SNK-125 will allow patients recovering from retinal surgery to see clearly and avoid extensive head posturing, conferring a comfortable recovery and quick return to normal life.

The Problem: Treatment of glaucoma requires administration of therapeutic eye drops daily, or intracameral implants that require invasive injections.

Our Solution: Synakis has developed SNK-225: our novel biomaterial loaded with with prodrug formulations to deliver a long-acting treatment for glaucoma. Non-invasive administration of SNK-225 into the subconjunctival space provides a prolonged delivery of small molecule therapeutics which obviate the need for daily eye drops or intracameral injections.

The Problem: Use of biologic therapeutics to treat retinal degenerative diseases is hindered by rapid biologic degeneration and poor pharmacokinetics. Frequent intravitreal injections are required to achieve a therapeutic effect.

Our Solution: Synakis has developed SNK-325: our novel biomaterial combined with state-of-the-art protein engineering techniques to stabilize biologic therapeutics and mediate their extended delivery to the back of the eye. SNK-325 provides enhanced bioavailability and a prolonged therapeutic window to reduce the frequency of injections.